about
Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas.Treatment of High-Risk T-NHL with Stem Cell Transplantation: A Single Center Experience.Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas.Safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphomaContributions of Subtypes of Non-Hodgkin Lymphoma to Mortality TrendsMicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid MalignanciesAutologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis.Autologous hematopoietic cell transplantation: an update for clinicians.Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an updateAlisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.Toward minimal conditioning protocols for allogeneic chimerism in tolerance resistant recipients.Guillain-Barré syndrome and severe infection following chemotherapy for peripheral T-cell lymphoma: A case report.A poor prognostic case of peripheral T-cell lymphoma in the base of tongue with chemotherapy followed by radiation therapy.Post-therapy ¹⁸F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma.Canine indolent and aggressive lymphoma: clinical spectrum with histologic correlation.Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients.
P2860
Q34156334-9AC046B4-7245-429C-BB90-32B9277CF96CQ34766846-FB3A32F1-24D1-4ED6-9C09-44310D292705Q35224833-53B3C983-1BF0-46C2-AFB6-B0271D8E96C8Q36283958-D00D8031-02FF-4137-8BCD-4CC7178E19CEQ36463900-ED66DE92-44AD-4F7D-962B-5A29FBF0311EQ36602853-CE7A5536-2CC1-4157-819F-F1904BC3D072Q36907048-64DE02F9-E996-4A24-AF1A-4606C41FDB98Q38248359-8B303468-C5B0-4169-98DF-801D5EA9DC1FQ38642648-0DE84D48-053C-4D33-9F32-E3DE9BA52223Q39244395-420D52E7-203C-4E51-B286-323E822B150FQ40729942-0E74932C-9525-4390-A733-2D570F1D5D1DQ41682425-CA3C59B9-8B4A-4B6B-93E5-5355F4382787Q41956081-48470EC3-FDA2-40E3-A432-BCB75CC4EF18Q43440577-CBE8FA83-9FCB-4DCE-BDFC-985D9898CDC0Q44955932-733D43ED-B094-47F3-A4D4-AC49DF1805A9Q47614980-4BBCE860-69F6-4625-90BA-6BDDA189F0DDQ51161466-F5E2E61C-E6A5-433C-8095-7E31E72665A0
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Therapies for peripheral T-cell lymphomas.
@en
Therapies for peripheral T-cell lymphomas.
@nl
type
label
Therapies for peripheral T-cell lymphomas.
@en
Therapies for peripheral T-cell lymphomas.
@nl
prefLabel
Therapies for peripheral T-cell lymphomas.
@en
Therapies for peripheral T-cell lymphomas.
@nl
P1476
Therapies for peripheral T-cell lymphomas.
@en
P2093
Kerry J Savage
P304
P356
10.1182/ASHEDUCATION-2011.1.515
P577
2011-01-01T00:00:00Z